BPMC   $129.46  0.14% Market Closed

Blueprint Medicines Corporation
Last Events:

2023-08-09 Trend Power changed from slow to almost flat.

2023-08-06 Trend pattern changed from канал to расходящийся клин с наклоном вверх.

2023-08-05 Signal in MACD changed from bullish weakening to bearish. Oscillator MACD is in the negative territory it crossed the signal line from the top and it crossed the zero line from the top. These factors mean that there is probably a falling trend. Last signal: main and signal line crossing.

2023-08-04 Signal in Stochastic changed from bullish weakening to bearish. The stochastic indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: down-crossing the middle level.

2023-08-04 Signal in MACD changed from bullish to bullish weakening. Oscillator MACD is in the positive territory it's higher than the signal line and falls. These factors mean that the growing trend persists, but the growth rate is declining. Last signal: up-crossing the middle level.

2023-08-04 Signal in RSI changed from bullish weakening to bearish. RSI indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: exit from the overbought zone.

2023-08-04 Signal in EMA100 changed from bullish reversal to bearish reversal. The price is trying to cross down the moving average line If the intersection will be successful, then a downside trend can be formed.

2023-08-04 Signal in EMA50 changed from bullish reversal to bearish reversal. The price is trying to cross down the moving average line If the intersection will be successful, then a downside trend can be formed.


Current temperature: 0.64
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 14
Target Price Mean 130.36
Mean unverified/preliminary 130.36 / 130.36
Target Price Low / High 129.00 / 135.00
Median / STD DEV 129.00 / 2.17
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Buy Buy ActivelyBuy
rsi Sell Buy None
macd None None None
stoch None None None
ma20 Buy None None
ma50 None None None
ma100 ActivelyBuy Buy ActivelyBuy
Candlestick PatternJuly 17, 2025 Doji - is formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.
ISIN US09627Y1091
ceo Ms. Kathryn Haviland M.B.A.
Website https://www.blueprintmedicines.com
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.